Skip to main content

February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology

Leukemia, Oncology
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
Chase Doyle
Read More
Leukemia, Oncology
Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
Read More
Leukemia, Oncology
Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL
Phoebe Starr
Read More
Leukemia, Oncology
Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
Chase Doyle
Read More
FDA Approvals
The Hematologic Drug Pipeline: Exciting New Treatment Options Looming
Phoebe Starr
Read More
FDA Approvals
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
Phoebe Starr
Read More
FDA Approvals
Venetoclax Shows Strong Activity in CLL
Phoebe Starr
Read More
Value-Based Care Must Be Linked to Improved Clinical Outcomes
James T. Kenney, RPh, MBA
Read More
Page 2 of 2
Results 11 - 18 of 18